Fluorouracil, High-Dose Folinic Acid, Low-Dose α-2b Interferon and Dipyridamole in the Treatment of Advanced Colorectal Cancer. A Pilot Study

Zaniboni, Alberto; Marpicati, P.; Simoncini, E.; Montini, E; Meriggi, Fausto; Arcangeli, G.; Bonera, F.; Braga, M.; Ragni, Fulvio; Marini, G

doi:10.1080/1120009x.1991.11739089

Journal of Chemotherapy

1991

DOI: 10.1080/1120009x.1991.11739089

|View full text |Cite

Fluorouracil, High-Dose Folinic Acid, Low-Dose α-2b Interferon and Dipyridamole in the Treatment of Advanced Colorectal Cancer. A Pilot Study

Alberto Zaniboni

P. Marpicati

E. Simoncini

et al.

Abstract: Twenty-six patients with advanced colorectal cancer were treated with a combination based on multimodal biochemical modulation of 5-fluorouracil by means of high dose folinic acid, low-dose alpha-2b interferon and dipyridamole. The overall response rate was 42% (95% confidence intervals = 23%. 61%) with four complete remissions (15%). The median duration of response was 9 months and the median survival for responders was 15 months (all patients = 12 months). Toxic side effects included oral mucositis (grade II… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1993

1999

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-steroidal antiinflammatory drugs appear to warrant further study for prevention of colonic polyposis and subsequent colon cancer (10)(11)(12)(13)(14)(15)(16)(17). Based on existing knowledge of mechanisms (18-20) and Table 1 Results of clinical trials of coagulation-reactive in cancer published since the initial registry report (1) (24,25), ovarian cancer (26)(27)(28), and N-SCLC (29,30), and the combination of dipyridamole, interferon, and 5-fluorouracil in colon cancer (31)(32)(33).…”

mentioning

confidence: 99%

Registry of Clinical Trials of Antithrombotic Drugs in Cancer: Second Report

Zacharski

Donati²,

Rickles

1993

Thromb Haemost

View full text Add to dashboard Cite

The Subcommittee on Hemostasis and Malignancy of the Scientific and Standardization Committee determined at its meeting of July 8, L992, to update the registry of clinical trials of antithrombotic drugs in cancer that had been established previously (1). The purpose of this update is to summarrze progress made since the previous report. The goal is to discern patterns of responsiveness (should they exist) of human malignancy to this form of treatment that would serve as a guide to the design of new clinical trials as well as to new basic studies that would clarify mechanisms. The Subcommittee has affirmed its intent to include trials of drugs known to modulate platelet function and coagulation/fibrinolysis reactions even though mechanisms of effect on malignancy may be uncertain or even multiple. This subject was first reviewed in 198L (2). As of that date, the therapeutic effects of antiplatelet drugs, anticoagulants, fibrinolytic enzymes, or inhibitors of fibrinolysis had been the subject of

show abstract

mentioning

confidence: 99%

Registry of Clinical Trials of Antithrombotic Drugs in Cancer: Second Report

Zacharski

Donati²,

Rickles

1993

Thromb Haemost

View full text Add to dashboard Cite

show abstract

Cytokine-based biotherapy of gastrointestinal tumors

et al. 1994

View full text Add to dashboard Cite

Over the past 20 years the administration of cytokines has emerged as an important fourth modality for the treatment of human cancer. Advances in the field of therapy of gastrointestinal tumors have become a major focus of current research, given the lack of progress of conventional antineoplastic therapy in most of these tumors. Among the heterogeneous group of gastrointestinal malignancies, novel therapeutic strategies have been employed for each individual tumor type, and cytokines (interferon-alpha) have gained an established role in the treatment of advanced carcinoid tumors. Although our understanding of the mechanisms of biological response modification is still limited, further improvement in the management of gastrointestinal malignancies can be expected from multimodality therapy regimens employing cytokines in combination with other biological response modifiers, chemotherapeutic agents, active-specific immunotherapy, and immunotoxin- and radionuclide-conjugated monoclonal antibodies. A wide range of clinical and preclinical studies have been conducted in colorectal carcinoma; however, potential therapeutic benefit of cytokine-based biotherapy has not been fully defined. Therefore, largescale, i.e., multicenter, studies are required to quantify the potential therapeutic effects of cytokines in gastrointestinal tumors.

show abstract

Inhibition of Metastases by Anticoagulants

Hejna¹,

Raderer²,

Zielinski³

1999

JNCI Journal of the National Cancer Institute

225

144

View full text Add to dashboard Cite

Metastasis involves several distinct steps, including one in which the tumor cell, after entry into the bloodstream, comes to rest in a capillary located at the distant site where a metastatic tumor will ultimately form. Components of the blood-clotting pathway may contribute to metastasis by trapping cells in capillaries or by facilitating adherence of cells to capillary walls. Conceivably, anticoagulants could interfere with this step in the metastatic process. In this review, we have summarized current knowledge on the interaction of malignant cells, clotting factors, and anticoagulants. We used computerized (MEDLINE) and manual searches to identify studies done in humans, in animals, and in in vitro systems that were published in English between 1952 and 1998. We found many reports that the formation of metastatic tumors could be inhibited by heparin, a vitamin K antagonist (warfarin), and inhibitors of platelet aggregation (prostacyclin and dipyridamole). Despite these encouraging preliminary results and a compelling biochemical rationale, only limited information exists on the clinical use of anticoagulants for the prevention or treatment of metastatic cancer because there have been so few controlled and prospectively randomized studies on this topic. In view of the preliminary results, anticoagulants may hold promise for the prevention and treatment of metastases. We believe that larger controlled investigations are strongly warranted to evaluate the clinical potential of anticoagulants for the prevention and treatment of metastases in humans.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Fluorouracil, High-Dose Folinic Acid, Low-Dose α-2b Interferon and Dipyridamole in the Treatment of Advanced Colorectal Cancer. A Pilot Study

Cited by 4 publications

References 2 publications

Registry of Clinical Trials of Antithrombotic Drugs in Cancer: Second Report

Registry of Clinical Trials of Antithrombotic Drugs in Cancer: Second Report

Cytokine-based biotherapy of gastrointestinal tumors

Inhibition of Metastases by Anticoagulants

Contact Info

Product

Resources

About